Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Vopr Onkol ; 61(1): 40-4, 2015.
Article in Russian | MEDLINE | ID: mdl-26016144

ABSTRACT

Application of modern linear electron accelerators, equipped with precise navigation systems, maximum conformal dose delivery as well as imaging of irradiated focus significantly increased possibilities of escalating of doses of ionizing radiation in a selected volume with the necessary protection of the surrounding critical structures. These technological solutions and modern ideas about possibilities of remote beam radiation therapy resulted in a significant increase of the role of radiation therapy and, in particular, stereotactic radiotherapy in the treatment of patients with liver metastases. This technique allows creating locally in metastatic tumor site a high dose of ionizing radiation causing by that the destruction of the tumor. This promising direction in treatment of liver metastases significantly expanded possibilities of complex treatment and enabled us to provide specific assistance to those patients who have been rejected from other methods of treatment.


Subject(s)
Liver Neoplasms/secondary , Liver Neoplasms/surgery , Radiosurgery , Radiotherapy, Conformal/methods , Adult , Aged , Female , Humans , Liver Neoplasms/radiotherapy , Male , Middle Aged , Radiotherapy Dosage , Stereotaxic Techniques , Treatment Outcome
2.
Vopr Onkol ; 61(1): 121-4, 2015.
Article in Russian | MEDLINE | ID: mdl-26016157

ABSTRACT

Morbidity and mortality from pancreatic cancer is steadily increasing. Resectable cases are not more than 20%. Conventional schemes of chemoradiation and radiation therapy are durable over the time, have toxicity and low treatment outcomes. Many foreign authors consider as promising the technique of stereotactic radiotherapy, which is often used in pancreatic cancer and permit achieving high local control. At our institution there has been developed and introduced into clinical practice a method of stereotactic radiotherapy for the palliative treatment of patients with pancreatic cancer, which improved not only the duration but also the quality of life of patients.


Subject(s)
Palliative Care/methods , Pancreatic Neoplasms/surgery , Quality of Life , Radiosurgery , Female , Humans , Middle Aged , Pancreatic Neoplasms/diagnostic imaging , Survival Analysis , Tomography, X-Ray Computed , Treatment Outcome
3.
Vopr Onkol ; 61(1): 141-4, 2015.
Article in Russian | MEDLINE | ID: mdl-26016161

ABSTRACT

Since February 2012, in order to increase the effectiveness of treatment and quality of life of patients with disseminated disease, there was developed and implemented a method of stereotactic radiotherapy for metastatic lesion of lungs by tumors of different histological types. 20 patients were treated by stereotactic radiotherapy ROD 7 Gy in five sessions during 5 days. There were evaluated results of treatment and prospects of this method.


Subject(s)
Lung Neoplasms/radiotherapy , Lung Neoplasms/secondary , Quality of Life , Stereotaxic Techniques , Adult , Aged , Female , Humans , Lung Neoplasms/diagnostic imaging , Male , Middle Aged , Neoplasm Staging , Radiotherapy/methods , Radiotherapy Dosage , Tomography, X-Ray Computed , Treatment Outcome
4.
Vopr Onkol ; 61(6): 965-7, 2015.
Article in Russian | MEDLINE | ID: mdl-26995988

ABSTRACT

Brain metastases in breast cancer develop for 24-32 months after the detection of the primary tumor. The study included patients with brain metastases who were divided into three groups: the first group--with early chemoradiotherapy (CRT) without induction chemotherapy (IC) by capecitabine; the second group--with delayed CRT with 4 or 8 courses of IC by capecitabine; the third group (a historical control) who received only whole brain radiation therapy. The median time to progression of intracranial metastases was 15.3, 12 and 5 months, respectively. The median time to the intracranial progression significantly less in the third group (5 months) compared with the first (15.3 months) (p = 0.0007) and the second (12 months) (p = 0.027) groups. The overall survival rate was 22.1, 15.1 and 6.8 months in three groups, respectively.


Subject(s)
Antineoplastic Agents/administration & dosage , Brain Neoplasms/therapy , Breast Neoplasms/therapy , Capecitabine/administration & dosage , Chemoradiotherapy, Adjuvant , Cranial Irradiation , Adult , Aged , Brain Neoplasms/mortality , Brain Neoplasms/secondary , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Middle Aged , Russia/epidemiology , Survival Analysis , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...